US-based Virtual Incision has secured an $18m Series B funding for the development of miniaturised surgical robots.

Led by Sinopharm Capital and Bluestem Capital, the funding round involved additional investors such as PrairieGold Venture Partners.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Virtual Incision intends to use the funds to support the 510(k) premarket notification submission for its next-generation miniaturised robotically assisted surgical device (RASD) to the US Food and Drug Administration (FDA).

Virtual Incision president and CEO John Murphy said: “Closing this round of financing launches the development of our miniaturised surgical robot toward our next key milestones, including submission to the FDA for market clearance.”

The firm is developing the RASD to allow less-invasion during general surgery abdominal procedures that are currently performed using large, open incisions.

"Our robot is designed to be moved from suite to suite as needed, providing the surgical staff with much more flexibility when it comes to the tools being used."

RASD is designed as a small, dexterous and self-contained surgical robot that enables insertion through an umbilical incision in the abdomen.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The technology is said to leverage existing tools and techniques and does not require a special operating room or infrastructure.

Virtual Incision co-founder and chief technology officer Shane Farritor said: “The large footprint and dedicated operating suite required to house multi-port or single-port mainframe robots can limit access, especially in smaller hospitals that have only one robotic surgery system.

“In contrast, our robot is designed to be moved from suite to suite as needed, providing the surgical staff with much more flexibility when it comes to the tools being used during a procedure.”

The firm’s robotic platform employs artificial intelligence and machine learning technologies to track and guide instrument usage.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact